Drug Trial Radar · NCT04959981
A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC
Last checked: Nov 19, 2026Latest source record: Jul 25, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Sep 2, 2021
Primary completion
Apr 27, 2023
Study completion Apr 27, 2023
Sponsor
- Lead sponsor
- Erasca, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 13, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
* To evaluate the safety and tolerability of escalating doses of ERAS-007 or ERAS-601 in combination with other cancer therapies in study participants with advanced non-small cell lung cancer (NSCLC). * To determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of ERAS-007 or ERAS-601 administered in combination with other cancer therapies. * To evaluate the antitumor activity of ERAS-007 or ERAS-601 in combination with other cancer therapies. * To evaluate the PK profiles of ERAS-007 or ERAS-601 and other cancer therapies when administered in combination.
Conditions
- Advanced Non-squamous Non-small-cell Lung Cancer
Interventions
ERAS-007Drug
Administered orally
ERAS-601Drug
Administered orally
OsimertinibDrug
Administered orally
SotorasibDrug
Administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Limiting Toxicities (DLT)Time frame: Study Day 1 up to Day 22
- Maximum Tolerated Dose (MTD)Time frame: Study Day 1 up to Day 22
- Recommended Dose (RD)Time frame: Study Day 1 up to Day 22
- Adverse EventsTime frame: Assessed up to 24 months from time of first dose
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
City of Hope
Duarte, California
UC Irvine, Chao Family Comprehensive Cancer Center
Orange, California
UC Los Angeles
Santa Monica, California
University of Colorado
Aurora, Colorado
Massachusetts General Hospital
Boston, Massachusetts
Dana Farber Research Institute
Boston, Massachusetts
Henry Ford Health System
Detroit, Michigan
Hackensack University Medical Center (John Theurer Cancer Center)
Hackensack, New Jersey
Memorial Sloan Kettering Cancer Center
New York, New York
Sarah Cannon Research Institute (Tennessee Oncology)
Nashville, Tennessee
Virginia Cancer Specialists
Fairfax, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.